HUE045148T2 - Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére - Google Patents

Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére

Info

Publication number
HUE045148T2
HUE045148T2 HUE14730466A HUE14730466A HUE045148T2 HU E045148 T2 HUE045148 T2 HU E045148T2 HU E14730466 A HUE14730466 A HU E14730466A HU E14730466 A HUE14730466 A HU E14730466A HU E045148 T2 HUE045148 T2 HU E045148T2
Authority
HU
Hungary
Prior art keywords
bumetanid
parkinson
syndrome
treatment
neurodegenerative diseases
Prior art date
Application number
HUE14730466A
Other languages
English (en)
Inventor
Yehezkel Ben-Ari
Nathalie Dehorter
Philippe Damier
Constance Hammond
Original Assignee
B & A Therapeutics Inmed
Ct Hospitalier Universitaire Nantes
Inst Nat Sante Rech Med
Univ Aix Marseille
Univ Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by B & A Therapeutics Inmed, Ct Hospitalier Universitaire Nantes, Inst Nat Sante Rech Med, Univ Aix Marseille, Univ Nantes filed Critical B & A Therapeutics Inmed
Publication of HUE045148T2 publication Critical patent/HUE045148T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE14730466A 2013-05-31 2014-05-28 Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére HUE045148T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP13170183.1A EP2808391A1 (en) 2013-05-31 2013-05-31 Modulators of intracellular chloride concentration for treating neurodegenerative diseases with parkinsonian syndromes

Publications (1)

Publication Number Publication Date
HUE045148T2 true HUE045148T2 (hu) 2019-12-30

Family

ID=48520848

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE14730466A HUE045148T2 (hu) 2013-05-31 2014-05-28 Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére

Country Status (11)

Country Link
US (1) US9974763B2 (hu)
EP (2) EP2808391A1 (hu)
CA (1) CA2949910C (hu)
DK (1) DK3004353T3 (hu)
ES (1) ES2730023T3 (hu)
HR (1) HRP20191030T1 (hu)
HU (1) HUE045148T2 (hu)
PL (1) PL3004353T3 (hu)
PT (1) PT3004353T (hu)
TR (1) TR201908928T4 (hu)
WO (1) WO2014191471A1 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3388520A1 (en) * 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
EP3768251A4 (en) 2018-03-22 2022-12-07 Research Foundation Of The City University Of New York MODULATION OF NEURAL NKCC1 AS A THERAPEUTIC STRATEGY FOR SPASTICISM AND RELATED DISORDERS
US12544348B2 (en) 2018-04-12 2026-02-10 The J. David Gladstone Institutes Methods for treating APOE4/4-associated disorders
EP4051232A1 (en) 2019-10-31 2022-09-07 Neurochlore Liquid oral formulation of bumetanide
AU2022425382A1 (en) * 2021-12-30 2024-07-11 Neuropro Therapeutics, Inc. Pharmaceutical composition
IT202200008057A1 (it) * 2022-04-22 2023-10-22 Fondazione St Italiano Tecnologia Modulatori della concentrazione intracellulare di cloruro per l'uso nel trattamento del declino cognitivo

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
WO2011133215A1 (en) * 2010-04-19 2011-10-27 Health Research Inc. Method of identifying and treating a person having a predisposition to or afflicted with parkinson disease
JP2013536178A (ja) * 2010-07-26 2013-09-19 ニューロセラピューティクス ファーマ, インコーポレイテッド アリールスルホンアミド誘導体、組成物、および使用方法

Also Published As

Publication number Publication date
EP2808391A1 (en) 2014-12-03
WO2014191471A1 (en) 2014-12-04
US9974763B2 (en) 2018-05-22
DK3004353T3 (da) 2019-06-17
PL3004353T3 (pl) 2019-10-31
CA2949910C (en) 2022-09-13
TR201908928T4 (tr) 2019-07-22
PT3004353T (pt) 2019-06-18
US20160106693A1 (en) 2016-04-21
ES2730023T3 (es) 2019-11-07
EP3004353A1 (en) 2016-04-13
HRP20191030T1 (hr) 2019-09-06
CA2949910A1 (en) 2014-12-04
EP3004353B1 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
IL283943A (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
HUE056006T2 (hu) Kombináció Parkinson-kór kezelésére
IL256166B (en) Compounds for use in treating neuromuscular disorders
PT3811943T (pt) Composto para uso no tratamento de distúrbios oculares
HUE059041T2 (hu) Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására
EP2991670B8 (en) Sobetirome in the treatment of myelination diseases
PL3060252T3 (pl) Zastosowanie cząsteczek wiążących semaforynę-4D do leczenia zaburzeń neurodegeneracyjnych
BR112015022854A2 (pt) pró-farmacos de fumaratos e uso do mesmo no tratamento de várias doenças
HUE054783T2 (hu) Pridopidin Huntington-kór kezelésében
HUE043171T2 (hu) Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
PL3466425T3 (pl) Zastosowanie pochodnych glutarimidu w leczeniu chorób eozynofilowych
IL242163B (en) Combination therapy of an afucosylated cd20 antibody with a cd79b antibody-drug conjugate
HUE037179T2 (hu) Gyógyászati kompozíciók izom-rendellenességek kezelésére
ZA201603117B (en) Withanolides useful for the treatment of neurodegenerative diseases
HUE045148T2 (hu) Bumetanid parkinson-szindrómás neurodegeneratív betegségek kezelésére
EP3013824B8 (en) Carboline compounds usable in the treatment of neurodegenerative diseases
HUE040027T2 (hu) Taurourzodezoxikólsav (TUDCA) neurodegeneratív betegségek kezelésében történõ alkalmazásra
HRP20181980T1 (hr) Ciklezonid za liječenje dišnih puteva kod konja
ZA201507718B (en) The local treatment of inflammatory ophthalmic diseases
HRP20190219T1 (hr) Spojevi za tretman pretilosti i postupci za njihovu uporabu
LT2872145T (lt) Sujungti benzazepinai tureto sindromui gydyti
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
IL246148A0 (en) Treating brain disorders and biomarkers related thereto
EP2958570A4 (en) THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders